Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market Overview

The global oligonucleotide synthesis market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 13.5 billion by 2035, with a 7.9% CAGR during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of application area, the research and diagnostics segment holds the highest share (~60%) of the market.
• With regards to type of product synthesized, the active pharmaceutical ingredients segment dominates the global market.
• Based on the type of oligonucleotide synthesized, the antisense oligonucleotide segment holds the largest market share (more than 60%) in 2026.
• With respect to scale of operation, commercial segment captures the highest share (~80%) in 2026.
• With regards to therapeutic area, the rare diseases segment dominates the market with close to 45% of the market share.
• Based on the end-users, the pharmaceutical / biopharmaceutical companies capture the largest share in 2026.
• With respect to the company size, the large and very large companies hold the majority of the market share (~75%).
• In terms of geographical regions, North America captures the majority of the market share, and this trend is unlikely to change in the near future.

Key Market Statistics

• Market Size in 2026: $6.8 Billion
• Estimated Market Size in 2035: $13.5 Billion
• CAGR (2026-2035): 7.9%
• North America: Largest market in 2026 and fastest growing region

Market Overview

Oligonucleotides or oligos are short single stranded fragments of DNA or RNA molecules. These typically consist of 10-50 nucleotide chains with each chain made up of phosphate group, a sugar molecule (deoxyribose in DNA and ribose in RNA), and a nitrogenous base. These molecules play a crucial role in genetic testing, molecular testing and various other analytical testing procedures, such as artificial gene synthesis and polymerase chain reactions.

With the approval of the first antisense oligonucleotide drug, Vitravene, the applications of oligonucleotides in research and diagnostics, in addition to therapeutics, have significantly increased. Several preclinical and clinical studies have demonstrated the potential of oligonucleotides as a safe and effective treatment modality; these molecules possess unique characteristics, such as high target specificity and superior pharmacokinetic profile.

Presently, over 15 oligonucleotide-based therapies have been approved globally. In December 2024, Ionis Pharmaceuticals received the USFDA approval for TRYNGOLZA™ (olezarsen), as an adjunct to diet, for the adults suffering from familial chylomicronemia syndrome.  Earlier in June 2024, Geron announced the USFDA approval of RYTELO™ (imetelstat) for treating transfusion-dependent (TD) anemic patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS), who require more than four RBC units over eight weeks. Notably, these patients do not respond to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

Oligonucleotides are usually manufactured using chemical synthesis approaches, such as phosphoramidite synthesis and solid-phase synthesis (used for manufacturing small molecules). However, these approaches for production of synthetic oligonucleotides are fraught with various challenges, such as long development timelines, lack of purification techniques for oligonucleotides synthesized, regulatory and compliance-related issues, and lack of expertise among the developers. Therefore, several researchers and therapy / diagnostic developers in the oligonucleotide synthesis market prefer to outsource their oligonucleotide manufacturing operations to contract service providers, which possess the required manufacturing capabilities and expertise in the oligonucleotide synthesis market.

Further, it is worth noting that, with the rise in global disease burden, specifically, post the COVID-19 pandemic, there has been a significant rise in the demand for oligonucleotides, given their use in COVID-19 testing kits. Consequently, contract service providers are expanding their existing capacities and capabilities in order to cater to the growing demand. In addition, we believe that the growing oligonucleotide-based drugs pipeline, encouraging clinical trial results and extensive research activity in the domain, is likely to present lucrative market growth opportunities for custom / contract service providers, during the forecast period.

Recent Developments in the Oligonucleotide Synthesis Market

• In February 2026, University of Manchester researchers developed an ATP-free biocatalytic method using engineered enzymes PhoC_4, PPK, and TmAcK to synthesize nine diverse modified NTPs with 40-82% efficiency from nucleosides.
• In January 2026, FDA introduced flexible chemistry, manufacturing, and control requirements for cell and gene therapies to speed up product development and BLA submissions. This approach supports oligonucleotide-related advanced therapies by streamlining oversight while maintaining safety and efficacy in biologics production
• In January 2026, Codexis and Axolabs signed an evaluation agreement for ECO Synthesis oligonucleotide platform.
• In August 2025, Cohance Lifesciences announced INR 230 million investment for its integrated oligonucleotide platform and progress on new cGMP oligonucleotide building block manufacturing facility in India.
• In July 2025, Synoligo Biotechnologies launched new e-commerce website for the purpose of oligonucleotide synthesis, in order to enhance the ordering process and overall customer experience.
• In May 2025, Oligo Factory announced the portfolio expansion for inclusion of low-scale oligo synthesis capability.

Oligonucleotide Synthesis Market Trend

• Partnership Activity: Over 30% of these partnerships have been inked in the past two years. Interestingly, most of the agreements signed between the stakeholders were acquisition and manufacturing agreements.
• Clinical Trial Analysis: Close to 300 clinical trials have been registered across different geographical regions to evaluate various oligonucleotides. Majority (>50%) of these trials were registered in North America. Further, the maximum number of patients (19,590) have been enrolled in clinical trials conducted in Europe, which account for 26% of the overall enrollment.
• Installed Capacity: Maximum (49%) capacity for oligonucleotide manufacturing is installed in facilities located in North America. It is worth mentioning that, over the past few years, the oligonucleotide synthesis capacity installed in Asia-Pacific and rest of the world has also increased at a substantial pace. This is primarily driven by the technical advances, low labor costs and socio-economic reforms favoring the growth of specialty industries, such as the oligonucleotide industry.
• Annual Demand: The demand for oligonucleotides is projected to reach over 2,200 kgs in 2035, growing at a CAGR of 17%. In addition, the commercial and clinical demand for oligonucleotides is projected to reach 2,044 kgs and 152 kgs in 2035, respectively.

Industry Experts on Oligonucleotide Synthesis Market

The oligonucleotide synthesis market report features detailed transcripts of interviews held with the following industry stakeholders:

• Founder and Managing Director, Small Company, Germany
• Co-Founder and Managing Director, Small Company, India
• Chief Scientific Officer and Managing Director, Small Company, Germany
• Managing Director, Mid-sized Company, Germany
• Business Officer, Mid-sized Company, China
• Chem Lab Manager, Small Company, US
• Global Corporate Sales and Business Development, Small Company, Germany

Market Share Insights

Market Share by Type of Product Synthesized

• The oligonucleotide finished dosage occupies the highest share in 2026 and is expected to remain dominant during the forecast period.
• This can be attributed to the rising approval of oligonucleotide therapies in the coming years and higher profit margins for finished dosage forms.

Market Share by Scale of Operation

• Presently, the market is dominated by revenues generated from commercial scale synthesis of oligonucleotides and this trend (in terms of market share) is likely to remain same during the forecast period.

Market Share by Type of Oligonucleotide Synthesized

• Based on the type of oligonucleotide synthesized, the global oligonucleotide synthesis market is segmented into antisense, DNA, siRNA and other oligonucleotides.
• The antisense oligonucleotide segment occupies the highest share in 2026 and is expected to be dominant during the forecast period.
• With the rising number of approved siRNA and antisense oligonucleotides-based therapies for various rare diseases, genetic disorders and other disorders, these segments are likely to grow at a higher CAGR as compared to other types of oligonucleotides in the coming years.

Market Share by Company Size

• Presently, the market is dominated by large and very large players. This can be attributed to the fact that large and very large players have well-established facilities and capabilities to improve operational efficiencies and reduce the manufacturing cost of novel therapeutics.
• It is worth highlighting that mid-sized companies are likely to grow at a relatively higher pace in the coming years, as compared to small, and large and very large companies in the oligonucleotide synthesis market.

Market Share by Therapeutic Area

• The rare diseases segment occupies the highest share in 2026. However, cardiovascular disorders market segment is expected to witness substantial market growth in the coming years.

Market Share by Key Geographical Regions

• According to our oligonucleotide synthesis market forecast, the market in North America is likely to capture majority (45%) of the share, and this trend is unlikely to change in the future.
• It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR (10.7%), during the period 2026-2035.
• Detailed methodology across the global oligonucleotide synthesis industry and revenue generated across various segments is available in the full report.

Major Key Insights

Pipeline Analysis: Competitive Landscape of Oligonucleotide Synthesis Providers

The oligonucleotide synthesis market landscape features 110+ very large, large, mid-sized and small oligonucleotide synthesis providers offering custom oligonucleotide synthesis, oligonucleotide modification and oligonucleotide purification services, which are intended for research, diagnostic and therapeutic applications. Further, the most commonly adopted modification techniques for oligonucleotides include labeling modifications, backbone modifications and modified bases.

siRNA and Antisense Oligonucleotides are Most Widely Adopted for Gene Therapies

siRNA (short double-stranded RNA molecules) and antisense oligonucleotides (short single-stranded DNA or RNA molecules) are designed to bind complementary RNA and guide the RNA-induced silencing complex to block protein synthesis (translation). Both the molecules offer targeted approach to modulate gene expression via several therapies, available commercially. In June 2022, the USFDA approved the siRNA oligonucleotide-based medicine, Amvuttra (developed by Alnylam Pharmaceuticals) for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adult patients.

Market Analysis: Global Oligonucleotide Synthesis Market Size

The global oligonucleotide synthesis market is estimated to be worth $ 6.8 billion. Driven by the increasing potential of synthetic oligonucleotides as therapeutic agents and increase in the demand of oligo-based products, the oligonucleotide synthesis market is anticipated to grow at a CAGR of 7.9% during the forecast period.

Further, by 2035, in terms of type of oligonucleotide synthesized, majority of the market share is anticipated to be captured by antisense oligonucleotides. However, some interesting developments are taking place in the DNA synthesis market segment, specifically the advent of enzymatic DNA synthesis. This technological development can provide a breakthrough for the manufacturing of long DNA fragments, driving the market growth in this market segment. DNA synthesis is finding its application in development of cell and gene therapies as well in the niche area of DNA data storage.

Oligonucleotide Synthesis Market: Report Attribute / Market Segmentations

Key Report Attribute	Details
Historical Trend	Since 2018
Forecast Period	2026-2035
Future Trends	Till 2035
Current Market Size	$6.8 Billion
CAGR	7.9%
Application Area	Research and Diagnostics Therapeutics
Type of Product Synthesized	Active Pharmaceutical Ingredients Finished Dosage Forms
Type of Oligonucleotide Synthesized	Antisense DNA siRNA Other Oligonucleotides
Scale of Operation	Clinical Commercial
Therapeutic Area	Cardiovascular Disorders Genetic Disorders Liver Disorders Rare Diseases Other Disorders
End-users	Pharmaceutical/Biopharmaceutical Companies Academic And Research Institutes Hospitals
Company Size	Small Mid-sized Large and Very Large
Key Geographical Regions	North America Europe Asia-Pacific Rest of the World
Key Players	Agilent Technologies Ajinomoto Bio-Pharma Services CordenPharma Creative Biolabs Ella Biotech Eurofins Genomics Future synthesis Integrated DNA Technologies Kaneka Eurogentec LGC Biosearch Technologies Merck Microsynth Nitto Avecia Ribo Biotechnology STA Pharmaceutical / Wuxi STA Sumitomo Chemical Thermo Fisher Scientific TriLink Biotechnologies (Full list of more than 100 companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape Company Competitiveness Analysis Clinical Trial Analysis Big Pharma Initiatives Partnerships and Collaborations Recent Expansions Capacity Analysis Demand Analysis Market Forecast and Opportunity Analysis

Frequently Asked Questions

Question 1: How big is the oligonucleotide synthesis market?

Answer: The oligonucleotide synthesis market size is anticipated to be worth $ 6.8 billion.

Question 2: Who makes oligonucleotides?

Answer: Oligonucleotides are developed and manufactured in-house by various pharmaceutical companies and research institutes. However, for organizations lacking the required technical expertise and infrastructure, contract manufacturing organizations perform the manufacturing process.

Question 3: What is an oligo synthesizer?

Answer: An oligo synthesizer is an automated machine used to produce short DNA / RNA oligonucleotides at pilot or commercial scale. Examples include CS-OLIGO-D (developed by CSBio), Kilobaser one-XT (developed by Kilobaser) and Mermade 12 Synthesizer (developed by Biosearch Technologies).

Question 4: Who are the leading synthesis providers in the oligonucleotide synthesis market?

Answer: Examples of key oligonucleotide synthesis service providers (which have also been profiled in this report) include (in alphabetical order) Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Eurofins Genomics, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Nitto Avecia, Merck, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, Thermo Fisher Scientific, TriLink Biotechnologies.

Question 5: What are the most common types of agreement signed by the oligonucleotide synthesis providers?

Answer: The oligonucleotide synthesis providers are entering acquisitions, followed by manufacturing agreements and service alliances.

Question 6: What is the anticipated CAGR of oligonucleotide synthesis market?

Answer: The oligonucleotide synthesis industry is anticipated to grow at a CAGR of 7.9% by 2035.

Question 7: What are the leading market segments in the oligonucleotide synthesis market?

Answer: Currently, in terms of scale of operation, commercial scale manufacturing of oligonucleotide therapeutics captures the largest market share. Further, in terms of the type of product synthesized, API is expected to capture a prominent market share.